Phase 3 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue test, that is at a stage considered surgically removable and has not spread to distant parts of the body.
- People whose general physical health and ability to carry out daily activities is rated at a good level (rated 0 or 1 on a standard medical scale).
- People who have read, understood, and signed the official consent form for the study.
Who may not be able to join:
- People who currently have, or have previously had, an autoimmune disease (a condition where the immune system attacks the body's own tissues).
- People who require ongoing treatment with steroid medications or other medicines that suppress the immune system.
- People who have a history of symptomatic interstitial lung disease (a type of long-term lung condition causing symptoms).
- People who have a known allergy to any of the components of the study drug.
- People who are pregnant or currently breastfeeding.
- Men whose female partners are capable of becoming pregnant and who are not willing to use contraception during the study.
- People who have previously received chemotherapy, radiation therapy, targeted therapy, or immunotherapy for this cancer or any previous cancer.
- People with other medical conditions that, in the treating doctor's judgement, would make receiving the study drug unsafe or make it difficult to assess side effects (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hecheng Li, MD/PHD, Ruijin Hospital Shanghaijiaotong University School of Medicine
Phone: 19121652450
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
3-year overall survival rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.